1. Home
  2. KYMR vs KRYS Comparison

KYMR vs KRYS Comparison

Compare KYMR & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

SELL

Current Price

$106.49

Market Cap

9.1B

Sector

Health Care

ML Signal

SELL

Logo Krystal Biotech Inc.

KRYS

Krystal Biotech Inc.

SELL

Current Price

$327.66

Market Cap

9.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KYMR
KRYS
Founded
2015
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1B
9.6B
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
KYMR
KRYS
Price
$106.49
$327.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
24
12
Target Price
$139.35
★ $392.11
AVG Volume (30 Days)
★ 791.6K
264.1K
Earning Date
11-03-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 128.00
EPS
N/A
★ 3.62
Revenue
$39,211,000.00
★ $389,130,000.00
Revenue This Year
$167.23
$29.00
Revenue Next Year
N/A
$28.44
P/E Ratio
★ N/A
$88.72
Revenue Growth
N/A
★ 33.94
52 Week Low
$55.26
$183.03
52 Week High
$130.05
$382.54

Technical Indicators

Market Signals
Indicator
KYMR
KRYS
Relative Strength Index (RSI) 40.87 45.22
Support Level $100.63 $318.87
Resistance Level $121.24 $371.16
Average True Range (ATR) 5.07 10.24
MACD -0.31 -0.39
Stochastic Oscillator 36.08 29.01

Price Performance

Historical Comparison
KYMR
KRYS

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Share on Social Networks: